Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate Cancer

NCT00268892 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

278

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Degarelix
DRUG: Degarelix
DRUG: Degarelix

Sponsor

Ferring Pharmaceuticals